Skip to main content
Type at least 3 characters

5,618 articles

articles

Clinical Trial

Published on 19 May 2025

A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis

in Inflammation

  • Gyeong Ho Baek
  • Bo Ri Kim
  • Jung-Won Shin
  • Chang Hun Huh
  • Jungjoong Hwang
  • Sungmin Ko
  • Siwon Kim
  • Pil-Su Ho
  • Kyu-Han Kim
  • Chun Wook Park
Frontiers in Immunology
doi 10.3389/fimmu.2025.1560447
  • 4,590 views